# Tohoku University Venture Partners

> Tohoku University Venture Partners is a VC fund backing Medical. See 31 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sendai-shi, Japan
- Total investments: 31
- Last investment: May 2026
- Lead investor: 35%
- Last updated: Aug 2026
- Website: https://thvp.co.jp/
- Facebook: https://www.facebook.com/TOHOKUuVenturePartners/

Tohoku University Venture Partners is a VC fund in Sendai-shi focused on Medical and Manufacturing. THVP is a venture capital corporation for startup innovation. It was established in 2015 and is based in Nagoya, Japan.

## Contacts

5 contacts available for Tohoku University Venture Partners. Shizune tracks 1 team members at Tohoku University Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/tohoku-university-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $929k–$2.7M |
| Series A | $349k–$31M |
| Venture - Series Unknown | $1.3M–$8.8M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 9 | 29% |
| Manufacturing | 8 | 26% |
| Biotechnology | 7 | 23% |
| Health Care | 6 | 19% |
| Nursing and Residential Care | 5 | 16% |

49 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 29% |
| Venture - Series Unknown | 6 | 19% |
| Seed | 5 | 16% |
| Series B | 5 | 16% |
| Series C | 3 | 10% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Tetsuro Higuchi | Director and President | 4 | https://shizune.co/investors/profile/tetsuro-higuchi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Scohia Pharma | Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M |  | May 28, 2026 |  |
| Koeda | KOEDA is researching and developing medical devices that are safe, painless, and easy to use for acute cholecystitis. KOEDA will transform the management of cholecystitis. So far, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has been a notably difficult procedure carried out by skilled doctors at specific advanced centers. Althoughinserting a tube into the gallbladder is less invasive, it is complex, and there may be concerns regarding bile leakage. By combining clinical expertise with precision engineering, KOEDA addresses a clearly defined medical need in a growing global market and is currently moving forward on schedule for regulatory clearance and commercialization. |  | Venture - Series Unknown | Mar 31, 2026 |  |
| Storyline | Storyline is a company that use technology and design to address social challenges while building a sustainable society. |  | Venture - Series Unknown | Dec 24, 2025 |  |
| ElevationSpace | ElevationSpace offers high quality & well equipped workspaces giving tenants a nurturing environment . | $7.5M | Series B | Sep 17, 2025 |  |
| RevolKa | RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1.5M | Series A | May 20, 2025 |  |
| Rege Nephro | Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $15.2M | Series B | Oct 07, 2024 |  |
| Hakko Holdings | Hakko Holdings is a food-tech company that specializes in producing and manufacturing fermented plant-based food with unique fermentation technology for healthy and sustainable lives. |  | Seed | Oct 04, 2024 |  |
| Luxna Biotech | Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments. | $1.7M | Series C | Sep 06, 2024 |  |
| Koeda | KOEDA is researching and developing medical devices that are safe, painless, and easy to use for acute cholecystitis. KOEDA will transform the management of cholecystitis. So far, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has been a notably difficult procedure carried out by skilled doctors at specific advanced centers. Althoughinserting a tube into the gallbladder is less invasive, it is complex, and there may be concerns regarding bile leakage. By combining clinical expertise with precision engineering, KOEDA addresses a clearly defined medical need in a growing global market and is currently moving forward on schedule for regulatory clearance and commercialization. |  | Seed | Jun 03, 2024 |  |
| On-chip Biotechnologies | On-chip Biotechnologies is a medical research and manufcaturing company. | $1.3M | Venture - Series Unknown | May 07, 2024 |  |

10 of 31 investments shown.

## Co-investors
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 5 deals together
- [DCI Partners](https://shizune.co/investors/profile/dci-partners) — VC Fund, 3 deals together
- [Global Brain Corporation](https://shizune.co/investors/profile/global-brain-corporation) — VC Fund, 3 deals together
- [MIRAI SOUZOU](https://shizune.co/investors/profile/innovations-and-future-creation) — VC Fund, 3 deals together
- [77 Capital](https://shizune.co/investors/profile/77-capital) — VC Fund, 2 deals together
- [Beyond Next Ventures](https://shizune.co/investors/profile/beyond-next-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Climate Investors in Japan](https://shizune.co/investors/climate-investors-japan)
- [Health Care Investors in Japan](https://shizune.co/investors/health-care-investors-japan)
- [Health Care VC Funds in Japan](https://shizune.co/investors/health-care-vc-funds-japan)
- [Manufacturing Investors in Japan](https://shizune.co/investors/manufacturing-investors-japan)
- [Manufacturing VC Funds in Japan](https://shizune.co/investors/manufacturing-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)

## FAQ

### What does Tohoku University Venture Partners invest in?

Tohoku University Venture Partners invests primarily in Medical, Manufacturing and Biotechnology startups, most often at Series A and Venture - Series Unknown stage. Most of the 31 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Tohoku University Venture Partners's check size?

Tohoku University Venture Partners typically joins rounds of $929k–$2.7M at Seed, $349k–$31M at Series A and $1.3M–$8.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tohoku University Venture Partners participates in.

### How do I contact Tohoku University Venture Partners?

Public channels for Tohoku University Venture Partners include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Tohoku University Venture Partners?

The team at Tohoku University Venture Partners includes Tetsuro Higuchi (Director and President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co